Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors
Who is this study for? Patients with Cancer
What treatments are being studied? TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:
• Patients with advanced cancers that failed to current available therapies;
• Life expectancy \>12 weeks;
• Adequate heart, lung, liver, kidney functions;
• Available for tumor biopsy or cancerous effusions;
• Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
Locations
Other Locations
China
Second Affiliated Hospital of Guangzhou Medical University
RECRUITING
Guangzhou
Contact Information
Primary
Zhenfeng Zhang, MD, PhD
zhangzhf@gzhmu.edu.cn
+862039195966
Backup
Bingjia He, MD
464677938@qq.com
+862039195965
Time Frame
Start Date: 2021-01-01
Estimated Completion Date: 2035-01-01
Participants
Target number of participants: 40
Treatments
Experimental: TILs/CAR-TILs treatment
Obtain TILs/CAR-TILs from advanced solid tumor patients and infuse them back to evaluate safety and clinical efficacy of the treatment.
Authors
Related Therapeutic Areas
Sponsors
Leads: Second Affiliated Hospital of Guangzhou Medical University
Collaborators: Guangdong Zhaotai InVivo Biomedicine Co. Ltd.